MULTI-CHANNEL PHARMACEUTICAL MARKETING

Remaining competitive in today’s pharmaceutical marketing environment has become increasingly complex with a great deal of pressure falling on marketers to think inventively about reaching consumers and healthcare professionals. A mounting number of marketing platforms and channels used to reach customers and collect data along with heightened regulations have created a growing challenge for multi-channel marketing professionals. The pharmaceutical industry is at the cusp of a promising phenomenon and by uncovering leading channel-marketing strategies, attendees will discover unique aspects of a multi-channel approach that can be directly implemented within an organization.

Spotlight

Enobia Pharma

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.

Other Infographics
news image

Smart Pharmacovigilance

Infographic | May 23, 2021

Pharmacovigilance (PV) is essential to all life science organizations, ensuring that patients' health comes first. Various trends in global healthcare have transformed today’s PV function into a corporate asset that enhances brand value and contributes to new growth opportunities. However, existing safety systems impose a significant cost burden to operate.

Read More
news image

Summary of Chloroquine and Hydroxychloroquine Drug-Drug Interactions

Infographic | April 7, 2020

COVID-19 is a rapidly emerging and devastating pandemic disease. Recently, chloroquine (CQ) and hydroxychloroquine (HCQ) have been suggested for possible off-label use for patients suffering from a more severe clinical course.

Read More
news image

Latest Improvement on Pharmanews to Serve You Better

Infographic | April 16, 2020

Poised to give our readers and advertisers better services in spite of the COVID19 pandemic, Pharmanews–your global health journal has continued to improve on its services in terms of healthcare information dissemination, by keeping readers abreast of latest development in public health, especially on how to stay safe from the novel Coronavirus, as well as expanding our reach to over 250,000 readers per month.

Read More
news image

Do patients actually watch all those pharma TV ads?

Infographic | January 13, 2020

Fewer than one in eight chronic-disease sufferers say they watch when a drug commercial comes on TV, according to one recent study of community users. And for the millennials among them, the percentage is even less so. That’s despite the $5.1 billion spent by biopharma on the medium in 2018. We take a look at these data points and many others from two recent studies on the media habits of patients and doctors.

Read More
news image

Cancer Drugs Bring in Most Pharma Revenue

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Read More
news image

2021 global life sciences outlook

Infographic | August 24, 2021

The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.

Read More

Spotlight

Enobia Pharma

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.

Events